Compare FCPT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | NRIX |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2015 | 2020 |
| Metric | FCPT | NRIX |
|---|---|---|
| Price | $22.03 | $25.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $27.78 | ★ $34.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 10-28-2026 | 10-12-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | ★ 1.87 | N/A |
| EPS | 0.55 | ★ 3.26 |
| Revenue | ★ $294,132,000.00 | $76,987,000.00 |
| Revenue This Year | $9.88 | $786.93 |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | $38.42 | ★ $7.98 |
| Revenue Growth | 9.72 | ★ 99.31 |
| 52 Week Low | $20.86 | $10.38 |
| 52 Week High | $26.86 | $28.23 |
| Indicator | FCPT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 59.45 |
| Support Level | $20.86 | $24.61 |
| Resistance Level | $22.10 | $28.23 |
| Average True Range (ATR) | 0.40 | 1.23 |
| MACD | 0.15 | 0.43 |
| Stochastic Oscillator | 85.54 | 84.15 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.